Company intelligence / Profile preview

Woolsey Pharmaceuticals, Inc.

New York City, New York, United Stateswoolseypharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

BRAVYL has completed patient recruitment for high-dose cohorts in its ALS study as of late 2024. Early clinical data suggest it may reduce motor neuron death by targeting cellular mechanisms contributing to neuronal damage[6][8]. The company holds multiple patents covering oral formulations designed to improve swallowing ease for patients with dysphagia common in neurodegenerative disorders[7].

Therapeutic areas: Neurology
Modalities: Small molecule drugs (notably fasudil-based compounds)
Industry: Biotech

Drug pipeline

1 asset

bravyl

Partnerships

Licensed intellectual property from a major pharmaceutical company related to fasudil development[4]

Beyond the preview

Go deeper on Woolsey Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Woolsey Pharmaceuticals, Inc..

Explore the full profile